News & Events

07 - 22 - 2024

Apollo Therapeutics and the University of Oxford enter into drug discovery and development collaboration

Apollo Therapeutics will inject capital and expertise into pipeline of potentially lifesaving medici

01 - 02 - 2024

Apollo Therapeutics Announces Second Close Of Series C Financing Bringing Total Raised In Round To $260 Million

09 - 06 - 2023

Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital

11 - 14 - 2022

Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development

ICR joins University of Cambridge, Imperial College London, UCL and King’s College London as a str

08 - 01 - 2022

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

02 - 22 - 2022

Apollo Therapeutics and King’s College London enter into a strategic collaboration

Apollo grows its partnerships with world-leading research institutions in the UK, with King’s join

11 - 18 - 2021

Apollo Therapeutics Appoints Dr. Sanjay Aggarwal as Chief Medical Officer, Opens U.S. Facility

06 - 17 - 2021

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Adv